Shared laboratory space, services and equipment will boost UCL’s ability to tackle one of our most urgent global health challenges
There are currently no effective therapeutics for any of the neurodegenerative conditions that give rise to diseases like dementia, which is now the leading cause of death in England and Wales. The cost of neurological disease to the UK economy is estimated at £112 billion each year.
Collaboration is at the heart of the IoN-DRI programme and will improve opportunities for new breakthroughs in tackling neurological diseases. To support this world-class centre we are building for neurological research and treatment, we have partnered with charities like Alzheimer’s Society and Alzheimer’s Research UK, alongside government, the Medical Research Council and the NHS. The new facility will also house the operational headquarters of the UK Dementia Research Institute (UKDRI), which was established as part of the government's Challenge on Dementia 2020.
By strengthening the Queen Square Institute of Neurology's collaborations with its clinical partners across UCL, its partnership with the UK’s leading neurology hospital and the national network of the UK DRI centres, the facility will bring together world-leading expertise and offer unrivalled opportunities for multidisciplinary collaboration.
Our goal is to create the most comprehensive, coordinated neuroscience research hub in the world. By working together, we hope to conquer neurological diseases once and for all.